RedHill Biopharma (RDHL) Earnings Analysis

RedHill Biopharma (RDHL) next reports earnings on 2026-08-20, consensus EPS -435 USD. Last quarter (2025-09-05) it beat with EPS -1 USD vs -690 USD est (+99.9%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E -0.34.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does RDHL next report earnings?

Next earnings date2026-08-20
Consensus EPS estimate-435 USD
Revenue estimate0.02B

RDHL earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2025-09-05-1 USD-690 USD+99.9%Beat
2025-04-10-1 USD-690 USD+99.9%Beat
2024-10-039 USD-3.68 USD+344.6%Beat
2024-07-29-2 USD-0.3 USD-566.7%Miss

Beat rate: 3/4 (75%) over reported quarters with consensus data.

RDHL valuation and analyst view

Trailing P/E-0.34
Trailing EPS-2.29229 USD
Price / book0.29
Dividend yield0.00%
Market cap0.00B
Analyst consensusBuy (10 buy / 0 hold / 0 sell)

Related research pages

Frequently asked questions

When is RedHill Biopharma (RDHL)'s next earnings date?

RedHill Biopharma is next scheduled to report on 2026-08-20, with a consensus EPS estimate of -435 USD and revenue estimate of 0.02B.

Did RDHL beat earnings last quarter?

In its 2025-09-05 report, RDHL posted EPS of -1 USD versus a -690 USD estimate — a beat of 99.9%.

What is RDHL's earnings track record?

Over the last 4 reported quarters with consensus data, RDHL beat estimates 3 times (75%).

What is RDHL's current P/E ratio and EPS?

RDHL trades at a trailing P/E of -0.34 on trailing EPS of -2.2922880839843773 USD.

What do analysts rate RDHL?

Analyst consensus is "Buy" across 10 ratings (0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell).